Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trial
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
| Condition(s) | Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials. |
| Who can participate | Key Inclusion Criteria: * Presence of mutations in the ABCA4 gene * ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy) Key Exclusion Criteria: * The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy * Retinal disease other than ABCA4-related retinopathy * Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study. |
| Ages | 5 Years |
| Sex | All |
| Lead sponsor | Ascidian Therapeutics, Inc |
| Locations | San Francisco, California, United States; Gainesville, Florida, United States; Baltimore, Maryland, United States; Boston, Massachusetts, United States; Ann Arbor, Michigan, United States; Cincinnati, Ohio, United States (+2 more sites) |
| Start date | 2024-06-20 |
| NCT ID | NCT06445322 |
| Official listing | https://clinicaltrials.gov/study/NCT06445322 |